Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) Return on equity
Moderna, Inc.'s return on equity over the twelve months to 30 June 2026 was −39.0%, down 10.1 percentage points from fiscal 2025 (−28.9%). Over the past ten years it has ranged from −82.1% (fiscal 2018) to 146.1% (fiscal 2021); the current reading is higher than 40% of that period. That is above the Biotechnology industry median of −56.4% and below the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −28.9% | (0.10) |
| FY2024 | −28.8% | (0.18) |
| FY2023 | −28.6% | (78.86) |
| FY2022 | 50.3% | (95.81) |
| FY2021 | 146.1% | 186.07 |
| FY2020 | −40.0% | (1.99) |
| FY2019 | −38.0% | 44.11 |
| FY2018 | −82.1% | (143.01) |
| FY2017 | 60.9% | 8.90 |
| FY2016 | 52.0% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 96.6% |
| ARGX argenex SE compare | 27.1% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 23.5% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 14.7% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 14.0% |
| RPRX Royalty Pharma PLC compare | 8.42% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| MRNA Moderna, Inc. | −39.0% |
| RVMD Revolution Medicines, Inc. compare | −79.1% |
| Biotechnology industry median | −56.4% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement